QianJin Pharmaceutical released its semi-annual performance, with a net profit attributable to the parent company of 128 million yuan, a year-on-year increase of 8.5%
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, QianJin Pharmaceutical disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 1.818 billion yuan, a year-on-year decrease of 5.52%; net profit attributable to the parent company was 128 million yuan, a year-on-year increase of 8.5%; net profit excluding non-recurring gains and losses was 118 million yuan, a year-on-year increase of 6.58%; basic earnings per share were 0.3012 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments